News | February 16, 2009

Clinic Reduces Treatment Time by 75 Percent Using TomoTherapy System

February 16, 2009 - University Clinic Heidelberg, Germany reduces treatment times for the TomoTherapy Hi·Art system from between 40 to 75 percent, while at the same time improving plan quality by further reducing radiation dose to normal tissue.
Based on an in-depth planning study, University Clinic Heidelberg researchers anticipate that a reduction in treatment time of between 40 to 75 percent will be possible with next-generation delivery techniques currently in development by TomoTherapy. Detailed findings of the study will be published later this year.
University Clinic Heidelberg installed the Hi·Art treatment system in March 2006. In December 2008, the medical team, led by professor Jürgen Debus, M.D., professor Klaus Herfarth, M.D., and Florian Sterzing, M.D., treated its 500th cancer patient with TomoTherapy’s unique CT platform-based solution for image-guided, intensity-modulated radiation therapy (IG-IMRT).
“TomoTherapy is used in our clinic to treat a wide range of cancer cases. Because of its advanced capabilities over conventional linear accelerators, the system plays an important role for indications where a large volume is to be irradiated and avoidance of critical structures is paramount,” said Dr. Sterzing. “These cases can require longer treatment times to gain optimal results. However, with the advanced TomoTherapy delivery technique, our research indicates that we should be able to treat these most complex cases in as little as 25 percent of the time necessary now. This is with no compromise in the excellent plan quality to which we are accustomed. In fact, we believe treatment quality will be improved.”
Emphasizing that the enhancements will not just benefit cases involving large or complex tumors, Dr. Sterzing added: “Any treatment you do at the moment will likely be faster, and of even higher quality.”

For more information: www.tomotherapy.com and www.klinikum.uni-heidelberg.de/Radioonkologie-und-Strahlentherapie.251.0...

Related Content

Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
IBA ProteusOne proton therapy system
News | Proton Therapy | January 29, 2020
January 29, 2020 — IBA (Ion Beam Applications S.A.) announced that it has signed a contract and received a major down
Philips launches Azurion with FlexArm to set new standard for the future of image-guided procedures

Philips launches Azurion with FlexArm to set new standard for the future of image-guided procedures.

News | Radiology Imaging | December 12, 2019
December 12, 2019 — Philips and the Regional Medical Center
Patient Treatments With ViewRay's MRIdian Linac Begin in New England
News | Image Guided Radiation Therapy (IGRT) | October 08, 2019
ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac...
Varian Unveils Ethos Solution for Adaptive Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian...
ASTRO 2019 to Feature Clinical Experience and Patient Outcomes With Viewray MRIdian
News | Image Guided Radiation Therapy (IGRT) | September 11, 2019
ViewRay Inc. announced that the company's MRIdian and MRIdian Linac magnetic resonance imaging (MRI)-guided radiation...
Beamscan MR 3D water phantom – the first 3-D water phantom for magnetic resonance (MR)-guided radiotherapy
News | Radiation Therapy | August 27, 2019
Radiation dosimetry company announced plans to exhibit its full range of radiation therapy dosimetry solutions for...